Methodologically, CD4 epitope discovery has been limited by MS sensitivity and variable prediction accuracy; a high-throughput class II profiling platform (EliteMHCII) spanning 24 common alleles increases the throughput and allele coverage of helper-epitope mapping and provides a scalable route to chart the PCa class II immunopeptidome across global HLA diversity (152). This evidence concerns the gene CD4 and posterior cortical atrophy.